FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1587585344> ?p ?o ?g. }

• W1587585344 endingPage "14" @default.
• W1587585344 startingPage "5" @default.
• W1587585344 abstract "The overactive bladder (OAB) syndrome can be treated with behavioural, surgical and/or pharmaceutical interventions, mainly represented by antimuscarinic drugs. Solifenacin is a new antimuscarinic with selectivity for the bladder and it demonstrated good effectiveness, safety and tolerability. Scope of the present study is to investigate the pharmacoeconomic performance of the treatment with solifenacin, when compared to tolterodine and placebo, in Italian patients with OAB. The economic evaluation is performed with a simulation model, based on a Markov chain. The time horizon of the simulation is 52 weeks, with a 1-week cycle. The model simulates the outcomes and costs of the treatment with solifenacin (5 mg/die), tolterodine ER (4 mg/die) and no treatment in a cohort representative of the Italian population with OAB (estimated in about 1,400 thousands patients). The cost analysis is conducted mainly in the perspective of the patient, since drugs for the treatment of OAB are currently not included in the Italian reimbursement list. The results show that both treatments produce significative improvements in symptoms and quality of life, with an increase in costs of about 540-640 Euro/year with solifenacin and of 680-780 Euro/year with tolterodine. In the cost-utility analysis, solifenacin dominates tolterodine since it results more effective and less costly, and its cost cost-utility ratio with respect to no treatment is in the range 7,600-18,600 Euro/QALY. In the subgroup of patients incontinent at baseline and who best respond to the therapy (responders), the increase in costs with solifenacin results of about 100-400 Euro/year and the cost-utility ratio is 600-4,200 Euro/QALY. A supplementary scenario has been elaborated to explore the consequences of a hypothetical reimbursement decision by the Italian NHS. In this scenario, the NHS cost perspective is considered and the antimuscarinic drugs are assumed to be reimbursed at a half of the current retail price only to incontinent and responder OAB patients. The overall expenditure of such a decision, which yields clear health outcomes, is estimated in about 23 millions Euro, with a cost-utility ratio of about 600-2,400 Euro/year, suggesting an efficient allocation of sanitary resources." @default.
• W1587585344 created "2016-06-24" @default.
• W1587585344 creator A5014024898 @default.
• W1587585344 creator A5057388317 @default.
• W1587585344 date "2008-03-15" @default.
• W1587585344 modified "2023-10-09" @default.
• W1587585344 title "Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis" @default.
• W1587585344 doi "https://doi.org/10.7175/fe.v9i1.210" @default.
• W1587585344 hasPublicationYear "2008" @default.
• W1587585344 type Work @default.
• W1587585344 sameAs 1587585344 @default.
• W1587585344 citedByCount "0" @default.
• W1587585344 crossrefType "journal-article" @default.
• W1587585344 hasAuthorship W1587585344A5014024898 @default.
• W1587585344 hasAuthorship W1587585344A5057388317 @default.
• W1587585344 hasBestOaLocation W15875853441 @default.
• W1587585344 hasConcept C112930515 @default.
• W1587585344 hasConcept C126322002 @default.
• W1587585344 hasConcept C126894567 @default.
• W1587585344 hasConcept C142724271 @default.
• W1587585344 hasConcept C197934379 @default.
• W1587585344 hasConcept C204787440 @default.
• W1587585344 hasConcept C2778375690 @default.
• W1587585344 hasConcept C2778941218 @default.
• W1587585344 hasConcept C2779502394 @default.
• W1587585344 hasConcept C2781020410 @default.
• W1587585344 hasConcept C2908647359 @default.
• W1587585344 hasConcept C3019080777 @default.
• W1587585344 hasConcept C71924100 @default.
• W1587585344 hasConcept C99454951 @default.
• W1587585344 hasConceptScore W1587585344C112930515 @default.
• W1587585344 hasConceptScore W1587585344C126322002 @default.
• W1587585344 hasConceptScore W1587585344C126894567 @default.
• W1587585344 hasConceptScore W1587585344C142724271 @default.
• W1587585344 hasConceptScore W1587585344C197934379 @default.
• W1587585344 hasConceptScore W1587585344C204787440 @default.
• W1587585344 hasConceptScore W1587585344C2778375690 @default.
• W1587585344 hasConceptScore W1587585344C2778941218 @default.
• W1587585344 hasConceptScore W1587585344C2779502394 @default.
• W1587585344 hasConceptScore W1587585344C2781020410 @default.
• W1587585344 hasConceptScore W1587585344C2908647359 @default.
• W1587585344 hasConceptScore W1587585344C3019080777 @default.
• W1587585344 hasConceptScore W1587585344C71924100 @default.
• W1587585344 hasConceptScore W1587585344C99454951 @default.
• W1587585344 hasIssue "1" @default.
• W1587585344 hasLocation W15875853441 @default.
• W1587585344 hasLocation W15875853442 @default.
• W1587585344 hasOpenAccess W1587585344 @default.
• W1587585344 hasPrimaryLocation W15875853441 @default.
• W1587585344 hasRelatedWork W1501189048 @default.
• W1587585344 hasRelatedWork W1994231517 @default.
• W1587585344 hasRelatedWork W2056879803 @default.
• W1587585344 hasRelatedWork W2064415662 @default.
• W1587585344 hasRelatedWork W2068329898 @default.
• W1587585344 hasRelatedWork W2132551029 @default.
• W1587585344 hasRelatedWork W2365289793 @default.
• W1587585344 hasRelatedWork W2406257615 @default.
• W1587585344 hasRelatedWork W2620675306 @default.
• W1587585344 hasRelatedWork W4252256305 @default.
• W1587585344 hasVolume "9" @default.
• W1587585344 isParatext "false" @default.
• W1587585344 isRetracted "false" @default.
• W1587585344 magId "1587585344" @default.
• W1587585344 workType "article" @default.